FDA panel endorses Allos' lymphoma drug Folotyn

09/3/2009 | Reuters

An FDA panel voted 10-4 to recommend the approval of Folotyn, Allos Therapeutics' candidate for peripheral T-cell lymphoma. The experts concluded that although the rate of patient response was not impressive overall, clinical results were strong enough to demonstrate Folotyn's benefit to certain PTCL patients who failed to respond to other therapies.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN